what does a glp-1 agonist do Medications: Everything You Need to Know GLP-1 Receptor Agonists as Treatments

Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors

Sales of antiobesity drugs hit $1.1 billion in the second quarter of 2023.

Injection-site reactions and worsening of pre-existing diabetic retinopathy are also relevant clinical concerns

Oral dosing 14mg vs 2000mg ER, T2D first-line outcomes.

There is no argument that the drugs are much more potent and faster acting than your bodies natural GLP-1 hormones

GLP-1 medications are changing how people think about weight loss and how they actually lose weight, driving changes in views about obesity care among health systems and providers and affecting the broader US economy. These drugs hold the potential to help address what continues to be an increasing obesity problem in the US. A 2024 []